Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Third Generation Sequencing
4.2.2 Decreasing Costs for Genetic Sequencing
4.2.3 Increasing R&D Expenditure
4.3 Market Restraints
4.3.1 Limited Reimbursement Policy and Regulation for NGS
4.3.2 Ethical and Social Issues Associated with Sequencing
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Template Kits
5.1.2 Library Kits
5.1.3 Control Kits
5.1.4 Sequencing Kits
5.1.5 Others
5.2 By Technology
5.2.1 Next Generation Sequencing
5.2.2 Sanger Sequencing
5.2.3 Third Generation Sequencing
5.3 By Application
5.3.1 Clinical Investigation
5.3.2 Oncology
5.3.3 Forensics & Agrigenomics
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Illumina, Inc
6.1.3 Thermo Fisher Scientific
6.1.4 Oxford Nanopore Technologies
6.1.5 Agilent Technologies, Inc.
6.1.6 BGI
6.1.7 Bioline
6.1.8 Qiagen
6.1.9 Takara Bio Inc.
6.1.10 Fluidigm Corporation


7 MARKET OPPORTUNITIES AND FUTURE TRENDS